Trafalgar International (GCAN) Change in Accured Expenses (2016 - 2026)
Trafalgar International (GCAN) posted Change in Accured Expenses of $30000.0 for Q1 2026, up 200.0% on a QoQ basis from $10000.0 in Q4 2025, and little changed year-over-year from $30000.0 in Q1 2025.
Analysis
Trafalgar International (GCAN) Change in Accured Expenses (2016 - 2026) Analysis & Trends
Trafalgar International has reported Change in Accured Expenses for 11 years, with the latest figure at $30000.0 in Q1 2026.
- On a quarterly basis, Change in Accured Expenses changed 0.0% year-over-year to $30000.0 in Q1 2026; TTM through Mar 2026 was $90000.0, a 39.88% increase from a year earlier, with the FY2025 full-year figure at $90000.0, up 125.0% from the prior year.
- Change in Accured Expenses was $30000.0 for Q1 2026 at Trafalgar International, up from $10000.0 in the prior quarter.
- The five-year high for Change in Accured Expenses was $30000.0 in Q1 2022, with the low at -$10000.0 in Q2 2022.
- Average Change in Accured Expenses over 5 years is $17491.2, with a median of $20000.0 recorded in 2022.
- The largest YoY upside for Change in Accured Expenses was 433.33% in 2022 against a maximum downside of 138.46% in 2022.
- Over 5 years, Change in Accured Expenses stood at $20000.0 in 2022, then sank by 63.25% to $7350.0 in 2023, then surged by 212.35% to $22958.0 in 2024, then tumbled by 56.44% to $10000.0 in 2025, then jumped by 200.0% to $30000.0 in 2026.
- The last three Change in Accured Expenses figures came in at $30000.0 (Q1 2026), $10000.0 (Q4 2025), and $30000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 2.32 Bn |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 1.20 Bn |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | - |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | - |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | 55.78 Mn |
| 8 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | -204.33 Mn |
| 9 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn | -4.00 Mn |
| 10 | Trafalgar International | 217,335.05 | 217,335.05 | - | 30,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 30,000.00 |
| Dec 31, 2025 | 10,000.00 |
| Sep 30, 2025 | 30,000.00 |
| Jun 30, 2025 | 20,000.00 |
| Mar 31, 2025 | 30,000.00 |
| Dec 31, 2024 | 22,958.00 |
| Sep 30, 2024 | 5,722.00 |
| Jun 30, 2024 | 5,660.00 |
| Mar 31, 2024 | 5,660.00 |
| Dec 31, 2023 | 7,350.00 |
| Sep 30, 2023 | 10,000.00 |
| Jun 30, 2023 | 30,000.00 |
| Mar 31, 2023 | 30,000.00 |
| Dec 31, 2022 | 20,000.00 |
| Sep 30, 2022 | 20,000.00 |
| Jun 30, 2022 | -10,000.00 |
| Mar 31, 2022 | 30,000.00 |
| Sep 30, 2021 | -6,000.00 |
| Jun 30, 2021 | 26,000.00 |
| Mar 31, 2021 | 31,000.00 |